This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995). By their nature, forward-looking statements involve risk and uncertainty. Forward-looking statements represent the company's judgment regarding future events, and are based on currently available information. Consequently the company cannot guarantee their accuracy and their completeness and actual results may differ materially from those the company anticipated due to a number of uncertainties, many of which the company is not aware of. For additional information concerning these and other important factors that may cause the company's actual results to differ materially from expectations and underlying assumptions, please refer to the reports filed by the company with the ‘Autorité des Marchés Financiers’.
Cegedim Strengths

From Healthcare 1.0 to Healthcare 3.0

Message from the Chairman

Q3-2013 Results

Focus on CRM & Strategic Data

Focus on Healthcare Professionals

Focus on Insurance & Services

Financial Communication

Conclusion
Cegedim Strengths
Video Cegedim Strengths
At the Heart of the Healthcare Ecosystem

Data, Software and IT Services Provider for the Healthcare Industry

- **196,000 users**
- **78,000* Pharmacists**
- **130,000* Physicians & Paramedics**
- **22 millions Beneficiaries in France**

* workstations
### 3 Divisions Serving 3 Types of Customers

#### CRM & Strategic Data
- **Presence**: 70 Countries
- **Services**:
  - Data Provider
  - Software
  - Market Research

<table>
<thead>
<tr>
<th>% Group Revenue</th>
<th>49%</th>
</tr>
</thead>
</table>

#### Healthcare Professionals
- **Presence**: For Physicians, Paramedics & Pharmacists
- **Services**:
  - Software
  - Leasing
  - Medication Database

<table>
<thead>
<tr>
<th>% Group Revenue</th>
<th>33%</th>
</tr>
</thead>
</table>

#### Insurance & Services
- **Presence**: For Major Insurance Players & Clients in all Business Sectors
- **Services**:
  - ITT for Healthcare Insurers
  - Electronic Reimbursement

<table>
<thead>
<tr>
<th>% Group Revenue</th>
<th>18%</th>
</tr>
</thead>
</table>
Cegedim Strengths

- Leading market positions in each of our divisions
- High barriers to entry
- Recognized portfolio of innovative and integrated solutions
- Stable and diversified customer base
- Strong presence along the healthcare value chain
- Long-standing shareholder support and experienced management
Unique Presence in the Healthcare Ecosystem

- Superior insights and understanding of the environment
- Significant competitive advantage to providing integrated solutions

Competitive offerings are siloed and address only specific customer needs

OneKey

CEGEDIM

MARKET RESEARCH

COMPLIANCE

CRM Licence

CRM SaaS Cloud

EHR EMR PRM

SOFTWARE FOR PHARMACISTS

FLOW

FINANCIAL LEASING

AD AT POS

E-BUSINESS

HR SERVICES

(...)

This document should not be distributed without Cegedim authorization – Copyright 2013
A Strategy Based on Innovation

- A strong power in the industry
- More than €60 million invested in R&D per year
- More than 1,000 R&D employees
- Globalized research network
From Healthcare 1.0 to Healthcare 3.0
Seismic Changes in Healthcare

Regulatory Drivers

- Stimulus for EHR adoption
- Healthcare reform
- Reimbursement policies that encourage the use of generic
- New payment model
- Transparency initiatives

- EHR – EMR solutions
- P4P compliant solutions
- Compliance offers
- Revenue cycle management
- e-RX
Seismic Changes in Healthcare

Economic Drivers

- Rising cost of care
- Continued reimbursement pressures
- Economic downturn

- Multichannel
- Help design strategy to maximize product potential while reducing the risk
- Targeting and segmentation tools
- OneKey (13.7m HCPs)
- Longitudinal patient Database (28m records)
- Pricing analytics
- Automation
- Healthcare payment integrity
Seismic Changes in Healthcare

Demographics / Consumers Drivers

- Aging population
- Rise in chronic conditions
- Consumers more involved
- Consumerism and emergence of retail healthcare models

- Patient portal
- Mobility
- Interconnectivity
- e-RX
- SaaS, Cloud solutions
Seismic Changes in Healthcare

Technological Drivers

- Interoperability
- Shift from collecting data to deriving information
- Adoption of lower cost and lower burden IT models (Cloud, SaaS, BPO)
- Smart mobile devices

- Mobility
- SaaS, Cloud, BPO
- Multiplatform solution
- Automation
- Strong R&D
- Our own network
Cegedim Helps the Successful Transformation

Regulatory Drivers
Economic Drivers
Demographics / Consumers Drivers
Technological Drivers

Healthcare 1.0
- Vertical integrated blockbuster model
- Drug centric model
- Physicians centric model
- Payer centric model

Healthcare 2.0
- Patent cliff
- Decrease in R&D productivity
- EHR incentive adoption
- Connectivity
- Healthcare IT modernization
- Enhance informed consumer

Healthcare 3.0
- Health IT
- eHealth
- Unified communication
- Interconnectivity
- Comparative effectiveness
- Link reimbursement to quality care
- Digital revolution
- Multichannel engagement model
- Real world evidence with real-time tracking
- Informed consumer
- Consumer involvement

- Improve Population Health
- Focus on Cost and Quality
The Market and Cegedim

Jean-Claude Labrune
Chairman & CEO
Q3-2013 Results
9M-2013: Key Take Aways

✓ FINANCIAL

- Revenues decreased by 0.5% on a L-f-L basis
- EBITDA increased by 2.5% to €90.5m
- EBITDA margin increased by 60 bps to 14.0%
- EBIT* increased by 7.9% to €45.2m
- Net financial debt increased by €31m

✓ ACHIEVEMENTS

- CRM & Strategic Data and Healthcare Professionals benefited from orders postponed in Q2
- Insurance & Services continued to step up its growth
- Cost-containment effort maintained
- Priority still on debt reduction

Target maintained for 2013 of 50 bps improvement in operating margin with stable revenues

* before special items
Q3-2013 Key Figures per Division

**CRM & Strategic Data**
- Revenue*: €108.1m (1.7%)
- EBITDA: €12.5m (131.8%)
- 51% of Q3 2013 Group Revenue

**Healthcare Professionals**
- Revenue*: €65.3m (6.4%)
- EBITDA: €14.3m (61.0%)
- 31% of Q3 2013 Group Revenue

**Insurance & Services**
- Revenue*: €37.6m (11.1%)
- EBITDA: €8.3m (45.1%)
- 18% of Q3 2013 Group Revenue

As announced, Q3 benefited from orders postponed in Q2

* change expressed on an L-f-L basis
9M-2013 Key Figures per Division

**CRM & Strategic Data**
- Revenue* (4.2)%
  €322.7m
- EBITDA (5.7)%
  €22.0m

50% of 9M 2013 Group Revenue

**Healthcare Professionals**
- Revenue* 1.9%
  €210.9m
- EBITDA (3.4)%
  €42.0m

32% of 9M 2013 Group Revenue

**Insurance & Services**
- Revenue* 7.4%
  €114.7m
- EBITDA 23.4%
  €26.5m

18% of 9M 2013 Group Revenue

* change expressed on an L-f-L basis

Online with full year targets
**9M 2013 Group Revenue**

**Revenue Evolution**

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>Organic</th>
<th>Structure</th>
<th>Currency</th>
<th>Reported</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3</td>
<td>€207.6m</td>
<td>4.7%</td>
<td>0.0%</td>
<td>(3.1)%</td>
<td>1.7%</td>
<td>€211.0m</td>
</tr>
<tr>
<td>9M</td>
<td>€660.9m</td>
<td>(0.5)%</td>
<td>0.3%</td>
<td>(1.7)%</td>
<td>(1.9)%</td>
<td>€648.2m</td>
</tr>
</tbody>
</table>

*Mainly JPY, USD, and GBP*

- Positive impact from orders postponed in Q2
- Divestment of Pharmapost on April 30th, 2012
- Acquisition of ASP Line on July 1st, 2012

Management remains confident that it will meet its 2013 targets

**9M 2013 Revenue Breakdown**

- CRM & Strategic Data: 50%
- Healthcare Professionals: 32%
- Insurance & Services: 18%

- France: 57%
- EMEA ex. France: 26%
- Americas: 13%
- APAC: 4%
### All Divisions Posted L-f-L Revenue Growth in Q3

<table>
<thead>
<tr>
<th>CRM &amp; strategic data</th>
<th>Healthcare Professionals</th>
<th>Insurance &amp; services</th>
<th>Cegedim Group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Quarterly Organic Growth</strong></td>
<td><strong>Quarterly Organic Growth</strong></td>
<td><strong>Quarterly Organic Growth</strong></td>
<td><strong>Quarterly Organic Growth</strong></td>
</tr>
<tr>
<td>(3.0)%</td>
<td>3.3%</td>
<td>3.9%</td>
<td>0.1%</td>
</tr>
<tr>
<td>(10.6)%</td>
<td>(3.0)%</td>
<td>7.4%</td>
<td>(5.4)%</td>
</tr>
<tr>
<td>1.7%</td>
<td>6.4%</td>
<td>11.1%</td>
<td>4.7%</td>
</tr>
<tr>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
<td>Q1</td>
</tr>
</tbody>
</table>

**Q3**
- Benefited from orders postponed in Q2
- Continued to step up its growth
- Benefited from orders postponed in Q2
- (0.5)% L-f-L Online with FY target

**9M**
- (4.2)% L-f-L
- 1.9% L-f-L
- 7.4% L-f-L

This document should not be distributed without Cegedim authorization – Copyright 2013
Expenses Continued to Decrease in Q3

- Around half of this decrease was due to FX effects
- Payroll costs, External Expenses and Purchases used declined in Q3 and 9M

(1) Expenses are defined as revenue minus EBITDA
EBITDA Evolution per Division

**CRM & strategic data**
- Q3 2012: €5.4m
- Q3 2013: €12.5m
- 132% increase

**Healthcare Professionals**
- Q3 2012: €8.9m
- Q3 2013: €14.3m
- 61% increase

**Insurance & services**
- Q3 2012: €5.7m
- Q3 2013: €8.3m
- 45% increase

**Cegedim Group**
- Q3 2012: €20.0m
- Q3 2013: €35.1m
- 76% increase

- **Q3**
  - EBITDA margin became 16.6%

**9M**
- **2012**
  - CRM: €23.3m
  - Healthcare Professionals: €43.5m
  - Insurance: €21.5m
  - Group: €88.3m
- **2013**
  - CRM: €22.0m
  - Healthcare Professionals: €42.0m
  - Insurance: €26.5m
  - Group: €90.5m
- **Chg.**
  - CRM: (5.7)%
  - Healthcare Professionals: (3.4)%
  - Insurance: 23.4%
  - Group: 2.5%

- **Q3**
  - Positive impact from CRM, Onekey and Market Research
  - Positive EBITDA on Q3 but on 9M negative impact from the French pharmacy market
  - All activities continue to grow
  - EBITDA margin increased by 60 bps
From EBITDA to EBIT

**EBITDA**

- **9M 2012**: €88.3m
- **9M 2013**: €90.5m

**D&A**

- **9M 2012**: €46.4m
- **9M 2013**: €45.3m

**Impairment of goodwill of €115m in June 2012**

**Special Items**

- **Q3 2012**: €2.3m
- **Q3 2013**: €1.1m

Special items divided by 2 in Q3

**EBIT**

- **9M 2012**: €(119.3)m
- **9M 2013**: €(5.1)m
- **9M 2012**: €40.0m
- **9M 2013**: €(77.5)m

9M EBIT before special items grow by 7.9% and margin increased by 64 bps
From EBIT to Consolidated Net Profit

- EBIT: €(77.5)m to €(32.3)m in 9M 2012-2013
- Cost of net financial debt: €8.9m impact from 2015 bond buyback in Q1
- Tax expense: €(2.6)m
- Consolidated net profit: €(111.1)m to €(4.8)m in 9M 2012-2013

In Q3 increase of only €0.5m

<table>
<thead>
<tr>
<th>Quarter</th>
<th>2012</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3</td>
<td>€(10.7)m</td>
<td>€(11.2)m</td>
</tr>
</tbody>
</table>

**EPS**

<table>
<thead>
<tr>
<th></th>
<th>9M 2012</th>
<th>9M 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS*</td>
<td>0.5</td>
<td>0.0</td>
</tr>
<tr>
<td>EPS</td>
<td>8.0</td>
<td>0.3</td>
</tr>
</tbody>
</table>

*before special items
9M 2013 Simplified Balance Sheet

Total Balance Sheet
0.6% €1,295.5m

Goodwill
(2.2)% €600.3m
46% of total assets

Shareholders Equity*
(3.7)% €409.4m
32% of total assets

* including minority interests

Net Cash*
€21.4m

Net Financial Debt
6.5% €506.4m
124% of equity

* Net cash equal cash and cash equivalent minus overdraft

This document should not be distributed without Cegedim authorization – Copyright 2013
9M 2013 Net Debt Evolution

Dec. 2012
Net Total Debt\(^{(3)}\)

Sept. 2013
Net Total Debt\(^{(3)}\)

\(^{(1)}\) Assets used by Cegelease for lease agreements and not transferred to banks.

\(^{(2)}\) Dividends received from equity method companies

\(^{(3)}\) Net total debt include liabilities under our employee profit sharing plans for €9.3m
**Capital Structure**

- **BPI France**: 15.0%
- **FCB wholly owned by Labruné family**: 52.6%
- **Public**: 32.0%

**Gross Debt by Source of Financing**

- **A**: Bond 2020 - 54%
- **B**: Bond 2015 - 30%
- **C**: Shareholder loan - 8%
- **D**: RCF - 1%
- **E**: Overdraft - 7%

**Credit Rating**

- **April 26, 2013**: B⁺, Stable Outlook
- **March 11, 2013**: B, Positive credit watch
- **October 9, 2012**: B, Stable outlook
Improved Debt Profile

Improved Maturity Profile

Robust Liquidity Profile

<table>
<thead>
<tr>
<th>as of September 2013</th>
<th>Total</th>
<th>Drawn</th>
<th>Available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Committed Facilities</td>
<td>€80m</td>
<td>€20m</td>
<td>€60m</td>
</tr>
<tr>
<td>Revolving Credit Facilities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net Cash</td>
<td>€22m</td>
<td>-</td>
<td>€22m</td>
</tr>
<tr>
<td>Group Other Facilities</td>
<td>€38m</td>
<td>€13m</td>
<td>€25m</td>
</tr>
<tr>
<td>Total</td>
<td>€140m</td>
<td>€33m</td>
<td>€107m</td>
</tr>
</tbody>
</table>

Headroom on Financial Covenants

<table>
<thead>
<tr>
<th>12-month period ending</th>
<th>Leverage Ratio</th>
<th>Interest Cover Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 31, 2012</td>
<td>2.80</td>
<td>4.95</td>
</tr>
<tr>
<td>June 30, 2013</td>
<td>3.20</td>
<td>3.25</td>
</tr>
</tbody>
</table>
Cegedim Strives for Realistic Mid Term Targets

Strategy

Growing Markets
New Products
New Market
Leading Positions

Profitability at 2009 level
Leverage ratio of 2.0x

Market Changes
FY 2013 Outlook

Margin Improvement Target in 2013 Maintained

For 2013, barring any significant changes in market trends, the target is to achieve:

<table>
<thead>
<tr>
<th>Outlook</th>
<th>FY 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
</tr>
<tr>
<td>CRM &amp; Strategic Data</td>
<td>(5%)</td>
</tr>
<tr>
<td>Healthcare Professionals</td>
<td>5%</td>
</tr>
<tr>
<td>Insurance &amp; Services</td>
<td>5%</td>
</tr>
<tr>
<td>Cegedim Group</td>
<td>0%</td>
</tr>
<tr>
<td><strong>EBIT</strong> (before special items)</td>
<td>(+50bps)</td>
</tr>
</tbody>
</table>

These projections are publicly disclosed on December 2013. The fact that Cegedim includes these projections in this presentation should not be taken to mean that these amounts continue to be our projections as of any subsequent date.

Significant Growth Opportunities

1. **CRM & Strategic Data**
   - Digital
   - Emerging Countries
   - Compliance

2. **Healthcare Professionals**
   - Computerization
   - Interconnectivity
   - Compliance
   - Best Practices

3. **Insurance & Services**
   - Healthcare System Efficiency
   - Payment Integrity
   - Interconnectivity

This document should not be distributed without Cegedim authorization – Copyright 2013
Focus on CRM & Strategic Data
CRM & Strategic Data Division

A Unique Combination of Services

Key Figures

<table>
<thead>
<tr>
<th>in € millions</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>527</td>
<td>511</td>
<td>488</td>
</tr>
<tr>
<td>EBITDA*</td>
<td>76</td>
<td>60</td>
<td>60</td>
</tr>
<tr>
<td>D&amp;A</td>
<td>25</td>
<td>27</td>
<td>28</td>
</tr>
<tr>
<td>EBIT*</td>
<td>51</td>
<td>34</td>
<td>33</td>
</tr>
</tbody>
</table>

* from recurring operations

Market Share

| CRM            | 36%¹ worldwide 200,000 users |
| OneKey         | 44%¹ worldwide 13.7m HCP²    |

Comprehensive Offers
Dr. Thomas Cruize, Oncologist

**General**
- Graduation: Cambridge, 1999
- No. of Affiliations: 3
- No. of Patients: HIGH
- Call Pressure: High
- Contact Channels: Email, Phone

**Prescription Behaviour**
- Stakeholder Type: Regulation & Control
- Geographic Level: National

**Market Access**
- Role: Inspector
- Phase: Post-launch
- Therapeutic Area: Oncology

**Influence**
- Influenced by: None
- Influencing: None
- Influence Scoring: 2
- No. of Publications: 0

**Digital**
- Uses Internet for:
  - E-detailing
  - Email
  - Internet Website
- Smartphone: Yes

---

How many HCP’s are likely to **prescribe my products**? Where are they **located**? What are their **preferences**?

What’s his **preferred channel to reach out to him**?

Who has the **best Prescription potential**?

Who can support and **help my product development**?

Who is a **Key Opinion Leaders at national/local level**?

Who is **Present, Active and Influent on Internet**?

...And much more
OneKey is ...

Superior Insights!

- Market Insights: 360° view of your Customer
- Cloud-based
- Accurate
- Accessible Anytime from Anywhere
- 13.7 Million Validated HCPs
Vincent PAVAN
Partner Product Integration, Senior Director
Unique Selling Proposition

CRM + CLM + Data in a Single Solution
With a Choice of Trained Creative Agencies
Two Processes at two different speeds Inter-Connected

Strategy

Target Segments & Messages

Creative Work

Validation

Presentation Definition

Detailed Insights

Personalized Strategy

Execution

Interactive Calls

Personalized Message

Live Interest Track
Demonstration
Olivier Cadou
Kadrige Chairman & Chief Executive Officer
Remote eDetailing (1/2)

Remote e-Detailing

1 to 1

Sales reps, Medical Liaison, CRA

1 to many
Remote eDetailing (2/2)
Multi-Channel Communication

- Face to face detailing
- Remote eDetailing
- Web
- Email

Cegelec & Kadrige: A Strategic Partnership
2.7 BILLIONS PEOPLE almost 40% of the World’s population are ONLINE

(Source: The world in 2013, ICT Facts and Figures, ITU 2012)

COMPUTERS (PCS): 1 Billion in use in 2008, 2 BILLIONS by 2015
SMARTPHONES: 1 Billion in use in 2012, 2 BILLIONS by 2015
TABLETS: 120 millions sold in 2013, 760 MILLIONS in use by 2016

(Source: Gartner Forrester Research 2012, Forrester Research Inc. 2012, Strategic Analytics 2012)
2G, 3G AND 4G NETWORK COVERAGE ARE VERY ERRATIC, EVEN IN BIG CITIES

WORLDWIDE MOBILE BROADBAND SERVICES ARE VERY EXPENSIVE

Price of mobile-broadband services by region (Prepaid 1GB)

(Source: The world in 2013, ICT Facts and Figures, ITU 2012)

(Source: World Bank 2011)
Kadrige Collaborative Technology

Data Preloading + Action Sharing + Data Synchronization = Application and Document Sharing

MOBILITY

COST SAVINGS

QUALITY

USER EXPERIENCE

EASE
Focus on Healthcare Professionals
A Unique Combination of Services

Key Figures

<table>
<thead>
<tr>
<th>in € millions</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>271</td>
<td>260</td>
<td>283</td>
</tr>
<tr>
<td>EBITDA*</td>
<td>69</td>
<td>59</td>
<td>59</td>
</tr>
<tr>
<td>D&amp;A</td>
<td>32</td>
<td>30</td>
<td>24</td>
</tr>
<tr>
<td>EBIT* (%)</td>
<td>13.6%</td>
<td>11.1%</td>
<td>12.4%</td>
</tr>
</tbody>
</table>

* from recurring operations

Market Share

Comprehensive Offers
The revolution of P4P: Cultural, Technical and Economic Impacts
Focus on Insurance & Services
Insurance & Services Division

A Unique Combination of Services

Key Figures

Market Share

Comprehensive Offers

IT Solutions
Leader
France

Reimbursement Systems
Leader
France

This document should not be distributed without Cegedim authorization – Copyright 2013
Cegedim SRH: A Story of Growth

Revenue (m€)

+18% CAGR

Number of payslips processed by TEAMS (in '000)

+85% CAGR
Jérôme Rousselot
Directeur

Benoit Garibal
Directeur Adjoint
Cegedim SRH: Key Take Aways

- #2 in France
- The new TEAMS\textsuperscript{RH} platform is a key alternative to old existing solutions
- High recurring revenue: more than 65%
- Average contract duration: 13 years
- Payslips acquisition trend: over 30,000 per year, mostly from companies over 2,500 employees
A Comprehensive Set of Services

✓ A multi HR modules platform

✓ Based on latest technologies
  • HTML5, CSS3, Jquery, Javascript
  • Cegedim IT Infrastructure

✓ From SaaS to full BPO

✓ A Unique code, version and database for all clients

✓ An Interactive payroll computation

✓ A Scalable system to fit legal changes and client organization evolution
Cegedim e-business

Cegedim Solution to Dematerialize, Pay and Archive all Documents
Cegedim e-business: Key Take Aways

From Purchase to Payment

1992 Dematerialization

Invoices

Payment

2013

First French Companies to be certified
A network of over 100,000 online members
Over 300 million of electronic documents exchanged per year
Over 1,000 large e-invoicing projects

A Steady Increase in Volume

Over 300m

2009 2010 2011 2012 2013
Worldwide Client References in all Sectors

GDF Suez
sanofi aventis
AIRFRANCE
EDF
COMPAGNIE GÉNÉRALE D’APPAÎTURAGE
Eligor
MICHelin
RATP
VINCI
OTIS
ESSILOR
Carrefour
Belgium
econocom
SAINT-GOBAIN
harry’s
MIDAS
DIAC
Location
SNCF
RTE
Gamm vert
Lindt
BOSCH
Des technologies pour la vie
Bouygues Telecom
INTER MUTUELLES ASSISTANCE
Schneider Electric
GSK
GlaxoSmithKline
sodexo
Bouygues Telecom
BNP PARIBAS
Pierre Fabre
DESCOURS & CABAUD
Négoce professionnel
IBM
Pfizer
europ assistance
CEGEDIM

This document should not be distributed without Cegedim authorization – Copyright 2013
Arnaud GUYON
Director BU Cegedim e-business
A Unique Combination of Value Added Offers

- **GIS e-invoicing**
  GIS e-invoicing service offers a tax compliant electronic exchange solution for suppliers and customers invoices

- **GIS workflow**
  GIS workflow service organizes the treatment and the validation of documents through a totally dematerialized process

- **GIS edi**
  GIS edi service offers an implementation of all supply EDI flows, including sales, logistics and financial documents

- **GIS sign&archive**
  GIS sign&archive allows the users to sign electronically all documents and to archive all types of documents

- **GIS payment**
  Range of solutions and services to facilitate and optimize migration to SEPA direct debit
Focus on Cegedim Global Payment

Deadline
February 1st 2014

Single Euro Payments Area

Offer

✓ Value Added Services
✓ Management of Payer Mandat
✓ MA€A Software Suite

Key Facts

✓ Over 150 Customers
✓ Over 350 million of Direct Debits per Year
✓ 50% in SaaS-Cloud
✓ 50% in-House
Financial Communication
Simplicity, Transparency, Clarity
Keep in Touch with Cegedim

SOCIAL NETWORKS
Twitter: @CegedimGroup

ANNUAL REVIEW
Registration Document
Interim Financial Report

SHAREHOLDERS GUIDE
Corporate Overview

EVENTS
Annual Investor Summit
Annual Results Conference
Confcall after each publication

MEETINGS
Broker Conference
One to One

WEBSITES
www.cegedim.com
www.cegedim.com/finance
New: Cegedim IR App

✓ Available early 2014
✓ For IOS and Android
Financial Agenda

January 28th
2013 Revenue

Available

This Document includes the Q3 2013 and 9M Financial Statements and Management Report
<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 28, 2014</td>
<td>2013 Revenue</td>
</tr>
<tr>
<td>March 10, 2014</td>
<td>2013 Results</td>
</tr>
<tr>
<td>March 11, 2014</td>
<td>Analysts Meeting</td>
</tr>
<tr>
<td>April 29, 2014</td>
<td>Q1 2014 Revenue</td>
</tr>
<tr>
<td>May 27, 2014</td>
<td>Q1 2014 Results</td>
</tr>
<tr>
<td>July 29, 2014</td>
<td>Q2 2014 Revenue</td>
</tr>
<tr>
<td>September 18, 2014</td>
<td>Q2 2014 Results</td>
</tr>
<tr>
<td>October 28, 2014</td>
<td>Q3 2014 Revenue</td>
</tr>
<tr>
<td>November 27, 2014</td>
<td>Q3 2014 Results</td>
</tr>
</tbody>
</table>
### Cegedim is a Group with Solid Foundations

<table>
<thead>
<tr>
<th>✓ Diversification</th>
<th>✓ Industry trends favor Cegedim businesses on mid term</th>
</tr>
</thead>
<tbody>
<tr>
<td>In term of clients, products, client concentration, geography</td>
<td>• Healthcare reform, transparency, pay for performance...</td>
</tr>
<tr>
<td></td>
<td>• Cegedim has a strong presence along the healthcare value chain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>✓ Steady Business Profile</th>
<th>✓ Cegedim remains committed to investments in innovation</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Critical size and strong market share across divisions</td>
<td>Recognized portfolio of innovation and integrated solutions</td>
</tr>
<tr>
<td>• Strong liquidity position, robust cash flow generation &amp; refinancing provides flexibility</td>
<td></td>
</tr>
<tr>
<td>• Long standing shareholder support and experienced management</td>
<td></td>
</tr>
</tbody>
</table>
We welcome your questions and comments

Jan Eryk UMIASTOWSKI
Chief Investment Officer
Head of Investor Relations

Janeryk.umiatowski@cegedim.com
www.cegedim.com/finance

TEL: +33 (0) 1 49 09 33 36